

# Paradigm Biopharmaceuticals Ltd

21:25 06 Aug 2019

## Paradigm Biopharmaceuticals files Investigational New Drug submission for ZilosulÒ with FDA

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has filed its first IND (Investigational New Drug) submission to the US FDA for an Expanded Access Program under which ten people from the US may be treated with ZilosulÒ (iPPS).

ZilosulÒ (iPPS) is a potential first-line therapeutic treatment for osteoarthritis and other diseases affecting the musculoskeletal system.

The ten Americans are anticipated to include some retired NFL players who have early-onset osteoarthritis and have also failed standard of care.

In males under the age of 60, osteoarthritis is over 3 times more prevalent in retired NFL players than in the general U.S. population.

This excess of early-onset arthritis may be due to the high incidence of injury in football.

The unmet clinical need

Osteoarthritis is a disabling disease leading to chronic pain, disability and a decreased quality of life.

It is the most common joint disorder in the developed world, with the lifetime risk of developing symptomatic knee osteoarthritis before age 85 years estimated in one US study at 44.7%.

Expanded Access Program

Expanded access, also called 'compassionate use', provides a pathway for patients to gain access to investigational drugs, biologics, and medical devices used to diagnose, monitor, or treat patients with serious diseases or conditions for which there are no comparable or satisfactory therapy options available outside of clinical trials.

FDA recognizes that osteoarthritis can be a serious disease with an unmet medical need for therapies that modify the underlying pathophysiology of the disease and potentially change its natural course to prevent long-term disability.

READ: Paradigm Biopharmaceuticals Ltd fully funded as it advances iPPS development

Through this Expanded Access Program, Paradigm seeks to provide ZilosulÒ (iPPS) to a limited number of patients who have failed other conservative therapies, and for whom access is requested by the treating physician.

**Price:** 1.69

**Market Cap:** \$334.31 m

### 1 Year Share Price Graph



April 2019    October 2019    March 2020

### Share Information

**Code:** PAR

**Listing:** ASX

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.5	1.08

**Sector:** Pharma & Biotech

**Website:** [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

### Company Synopsis:

*Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Paradigm plans to further its understanding of the potential utility of ZilosulÒ (PPS) for the treatment of BML (bone marrow edema lesions) associated pain and joint stiffness in a small group of knee OA patients while it prepares applications for a larger Phase 3 clinical trial.

**READ: Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial**

Paradigm's clinical and regulatory teams are continuing to work on submissions to the US FDA for the Phase 2/3 clinical trial in the very rare lysosomal storage disease (MPS), the Phase 3 clinical trial in Osteoarthritis and the Australian Therapeutic Goods Administration for the provisional approval of ZilosulÒ (iPPS) to treat osteoarthritis.

Paradigm is planning to submit these within the next two quarters of CY 2019.

Meanwhile, commercial discussions are ongoing regarding potential partnership deals and commercial transactions.

Expected future market updates prior to the end of CY 2019:

- File Expanded Access Program for 10 patients with US FDA Q3 CY 2019;
- File initial submission with the TGA for Provisional Approval Application of ZilosulÒ (iPPS) for treatment of osteoarthritis, Q3 CY 2019;
- Pre-IND meeting with US FDA Orphan Indication (MPS) Phase 2/3 clinical Trial Q4 CY 2019;
- Pre-IND meeting with US FDA osteoarthritis Phase 3 clinical trial Q4 CY 2019; and
- Commercial discussions - ongoing.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).